Quidel (QDEL) & Invivo Therapeutics (NVIV) Critical Analysis

Quidel (NASDAQ: QDEL) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Institutional and Insider Ownership

93.4% of Quidel shares are held by institutional investors. Comparatively, 11.5% of Invivo Therapeutics shares are held by institutional investors. 22.0% of Quidel shares are held by company insiders. Comparatively, 3.9% of Invivo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Quidel and Invivo Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quidel 0 0 5 1 3.17
Invivo Therapeutics 0 1 0 0 2.00

Quidel presently has a consensus price target of $54.20, suggesting a potential upside of 11.73%. Invivo Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 832.11%. Given Invivo Therapeutics’ higher possible upside, analysts clearly believe Invivo Therapeutics is more favorable than Quidel.

Volatility & Risk

Quidel has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.

Earnings and Valuation

This table compares Quidel and Invivo Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quidel $277.74 million 6.09 -$8.16 million ($0.24) -202.13
Invivo Therapeutics N/A N/A -$23.43 million ($0.85) -0.76

Quidel has higher revenue and earnings than Invivo Therapeutics. Quidel is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Quidel and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quidel -2.94% -3.02% -1.23%
Invivo Therapeutics N/A -134.23% -109.16%


Quidel beats Invivo Therapeutics on 10 of the 14 factors compared between the two stocks.

About Quidel

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply